Previous 10 | Next 10 |
home / stock / ipsey / ipsey news
Regulatory News: Disclaimer: Intended for international media and investor audiences only Ipsen (Euronext: IPN; ADR: IPSEY) reports that the U.S. Food and Drug Administration (FDA) has today announced its decision to postpone the planned Endocrinologic and Metabolic Drugs Adviso...
Regulatory News: Disclaimer: Intended for international media and investor audiences only Ipsen (Euronext: IPN; ADR: IPSEY) today announced the closing of the definitive merger agreement under which Ipsen has acquired Epizyme, Inc. (Epizyme). Pursuant to the transaction, Ipsen a...
Ipsen ( OTCPK:IPSEY ) ( OTCPK:IPSEF ) extended the expiration date for the tender offer to acquire cancer drug maker Epizyme ( NASDAQ: EPZM ) to Aug. 11, from Aug. 8. The French drugmaker noted that the decision was taken to allow additional time for expir...
Extension allows for satisfaction of the HSR Condition as outlined in the Merger Agreement Epizyme stockholders are encouraged to tender their shares to the offer today Regulatory News: Ipsen S.A. (Euronext: IPN; ADR: IPSEY) today announced that Hibernia Merg...
Ipsen's ( OTCPK:IPSEY ) ( OTCPK:IPSEF ) pancreatic cancer drug Onivyde did not meet the main goal of overall survival (OS) versus Novartis' ( NVS ) Hycamtin (topotecan) in a phase 3 trial in patients with small cell lung cancer (SCLC), who have progressed on or afte...
At the primary analysis, the trial did not meet its primary endpoint of overall survival (OS) The safety profile was consistent with previously reported studies of Onivyde ® (irinotecan liposomal injection) The clinical study results will be communicated with the regu...
Ipsen ( OTCPK:IPSEY ) ( OTCPK:IPSEF ) signed an agreement to advance Marengo Therapeutics two preclinical precision immuno-oncology candidates into clinic. Under the agreement, Ipsen will pay $45M upfront, with potential of up to a total of ~$1.59B if all milestones a...
Multi-year collaboration will sustain Ipsen’s presence in oncology by leveraging Marengo’s novel discovery of TCR Vβ -targeted precision T cell activation approach Ipsen to pay Marengo $45 million upfront with potential for additional milestone p...
Ipsen S.A. (IPSEY) Q2 2022 Earnings Conference Call July 28, 2022 7:30 AM ET Company Participants David Loew – Chief Executive Officer Aymeric Le Chatelier – Chief Financial Officer Howard Mayer – Head of Research and Development Confer...
The following slide deck was published by Ipsen S.A. in conjunction with their 2022 Q2 earnings call. For further details see: Ipsen S.A. 2022 Q2 - Results - Earnings Call Presentation
News, Short Squeeze, Breakout and More Instantly...
Ipsen SA ADR Company Name:
IPSEY Stock Symbol:
OTCMKTS Market:
Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases Canada NewsWire Ipsen enters into an option agreement to receive exclusive global rights to two candidates pursued under the collaboration Following development ...
Marengo Therapeutics Announces First Drug Candidate Nomination from Oncology Collaboration with Ipsen PR Newswire A Novel TCR Vβ bifunctional selective T cell activator molecule for solid tumor treatment Marengo to receive an associated milestone payment a...
Turnstone Biologics Corp. (TSBX) is expected to report $-0.73 for Q4 2023 Exro Technologies Inc (EXROF) is expected to report for Q4 2023 Boyd Gaming Corporation (BYD) is expected to report $1.43 for Q4 2023 Onto Innovation Inc. (ONTO) is expected to report $0.99 for Q4 2023 Motor...